The U.S. Food and Drug Administration has approved Quantum BioPharma Ltd.'s Investigational New Drug application for Lucid-MS, allowing the company to advance the multiple sclerosis candidate into Phase 2 clinical development. The announcement marks a significant step for the biopharmaceutical firm, which is positioning Lucid-MS as a potential first-in-class treatment that targets the underlying mechanisms of demyelination rather than solely modulating the immune system.
The upcoming Phase 2 trial is designed as a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of Lucid-MS in patients with multiple sclerosis. Clinical and radiological measures will be employed to assess outcomes. The company has begun trial start-up activities, including site selection, with patient enrollment and drug administration expected to commence as soon as possible. This progress follows favorable Phase 1 results, where Lucid-MS demonstrated a well-tolerated safety profile in healthy volunteers.
Lucid-MS is a patented new chemical entity that targets protein arginine deiminase 2 (PAD2), an enzyme implicated in myelin degradation. By inhibiting this enzyme, the drug aims to prevent and reverse myelin breakdown, a hallmark of multiple sclerosis. This neuroprotective approach differentiates it from existing MS therapies, which primarily focus on modulating the immune system. Preclinical models have shown that Lucid-MS can effectively prevent and reverse myelin degradation, offering a potential disease-modifying option for patients.
The FDA clearance is a pivotal regulatory milestone for Quantum BioPharma, which is dedicated to developing treatments for challenging neurodegenerative and metabolic disorders. The company's pipeline includes drug candidates in various stages of development, with Lucid-MS being its lead compound, developed through its wholly owned subsidiary, Lucid Psycheceuticals Inc.
As of March 31, 2026, Quantum BioPharma reported having more than $10 million in cash, digital assets, and liquid investments, providing the financial runway to initiate the Phase 2 trial. The company's strategic focus remains on advancing Lucid-MS through clinical development, with the hope of ultimately providing a new therapeutic option for the millions of people affected by multiple sclerosis worldwide.
The approval of the IND application is a critical step in the drug development process, and the initiation of Phase 2 trials represents a significant investment in the potential of Lucid-MS. If successful, this therapy could address an unmet medical need by offering a treatment that directly targets the neurodegenerative aspects of MS, potentially slowing or halting disease progression.
For more information about Quantum BioPharma and its pipeline, visit the company's newsroom at https://ibn.fm/QNTM.
